Journal article
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
JF Seymour, H Döhner, A Butrym, A Wierzbowska, D Selleslag, JH Jang, R Kumar, J Cavenagh, AC Schuh, A Candoni, C Récher, I Sandhu, TB del Castillo, HK Al-Ali, J Falantes, RM Stone, MD Minden, J Weaver, S Songer, CL Beach Show all
BMC Cancer | BIOMED CENTRAL LTD | Published : 2017
Abstract
Background: Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. Methods: We compared clinical outcomes for patients with AML-MRC treated with azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose cytarabine, or supportive care only) overall and within patient subgroups defined by cytogenetic risk (intermediate or poor) and age (65-74..
View full abstractGrants
Funding Acknowledgements
This study was funded by Celgene Corporation. The sponsor contributed to study design, collected and analyzed the data, and funded editorial support. The authors interpreted the data and the sponsor reviewed the manuscript for accuracy.